[go: up one dir, main page]

MX2007003603A - Metodos para preparar compuestos de indazol. - Google Patents

Metodos para preparar compuestos de indazol.

Info

Publication number
MX2007003603A
MX2007003603A MX2007003603A MX2007003603A MX2007003603A MX 2007003603 A MX2007003603 A MX 2007003603A MX 2007003603 A MX2007003603 A MX 2007003603A MX 2007003603 A MX2007003603 A MX 2007003603A MX 2007003603 A MX2007003603 A MX 2007003603A
Authority
MX
Mexico
Prior art keywords
methods
compounds
indazole compounds
preparing
formula
Prior art date
Application number
MX2007003603A
Other languages
English (en)
Inventor
Srinivasan Babu
Raymond Dagnino Jr
Michael Allen Ouellette
Bing Shi
Qingping Tian
Scott Edward Zook
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2007003603A publication Critical patent/MX2007003603A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La invencion se refiere a metodos para preparar compuestos de indazol que tienen la formula 1: (ver formula) o sales o solvatos de estos aceptables desde un punto de vista farmaceutico; los compuestos de la formula I son Utiles como agentes anti-angiogenesis y como agentes para modular y10 inhibir la actividad de proteinas quinasas, proporcionando, por lo tanto, tratamientos para el cancer u otras enfermedades asociadas con proliferacion celular mediada por proteinas quinasas.
MX2007003603A 2004-11-02 2005-10-21 Metodos para preparar compuestos de indazol. MX2007003603A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02
PCT/IB2005/003300 WO2006048745A1 (en) 2004-11-02 2005-10-21 Methods for preparing indazole compounds

Publications (1)

Publication Number Publication Date
MX2007003603A true MX2007003603A (es) 2007-05-21

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003603A MX2007003603A (es) 2004-11-02 2005-10-21 Metodos para preparar compuestos de indazol.

Country Status (15)

Country Link
EP (1) EP1809625A1 (es)
JP (1) JP2008518901A (es)
KR (1) KR20070058689A (es)
CN (1) CN101044138A (es)
AR (1) AR051753A1 (es)
AU (1) AU2005300311A1 (es)
BR (1) BRPI0517921A (es)
CA (1) CA2586176A1 (es)
IL (1) IL182096A0 (es)
MX (1) MX2007003603A (es)
NO (1) NO20072747L (es)
RU (1) RU2007114112A (es)
TW (1) TW200614990A (es)
WO (1) WO2006048745A1 (es)
ZA (1) ZA200702317B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP2134702B2 (en) 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
US20140248347A1 (en) 2011-09-30 2014-09-04 Pfizer Inc. Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
US9205078B2 (en) 2011-11-11 2015-12-08 Pfizer Inc. N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN103387565B (zh) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 阿西替尼的制备方法
CN103570696B (zh) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
EP3127900B1 (en) * 2014-03-31 2017-10-18 Senju Pharmaceutical Co., Ltd. Alkynyl indazole derivative and use thereof
CN104072484B (zh) * 2014-07-07 2016-07-06 渤海大学 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US10800846B2 (en) 2015-02-26 2020-10-13 Merck Patent Gmbh PD-1/PD-L1 inhibitors for the treatment of cancer
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EP3956321B1 (en) 2019-04-18 2024-03-20 Synthon B.V. Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt
CN112209861A (zh) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 一种阿昔替尼中间体化合物及其制备方法
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用
CN111440102B (zh) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 一种二硫代二苯甲酰胺类化合物的制备方法
US20240117030A1 (en) 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
EP4556466A4 (en) * 2022-08-08 2025-11-19 Beyang Therapeutics Co Ltd Protein Tyrosine Kinase Inhibitor and its Medical Uses
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
SI1585743T1 (sl) * 2002-12-19 2007-08-31 Pfizer Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
RU2357957C2 (ru) * 2003-03-03 2009-06-10 Эррэй Биофарма, Инк. Ингибиторы р38 и способы их применения
JPWO2005094823A1 (ja) * 2004-03-30 2007-08-16 協和醗酵工業株式会社 Ｆｌｔ−３阻害剤

Also Published As

Publication number Publication date
IL182096A0 (en) 2007-07-24
BRPI0517921A (pt) 2008-10-21
ZA200702317B (en) 2008-09-25
RU2007114112A (ru) 2008-12-10
JP2008518901A (ja) 2008-06-05
EP1809625A1 (en) 2007-07-25
CN101044138A (zh) 2007-09-26
AU2005300311A1 (en) 2006-05-11
WO2006048745A1 (en) 2006-05-11
AR051753A1 (es) 2007-02-07
NO20072747L (no) 2007-07-31
TW200614990A (en) 2006-05-16
KR20070058689A (ko) 2007-06-08
CA2586176A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
MX2007003603A (es) Metodos para preparar compuestos de indazol.
IN2014KN02886A (es)
IL260127B (en) mek inhibitors and methods of using them
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
TW200607505A (en) Fused heterocyclic kinase inhibitors
ATE532789T1 (de) Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
TW200801008A (en) Protein kinase inhibitors
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
TW200621721A (en) Methods of preparing indazole compounds
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2008001538A (es) Aril piridinas y metodos para su uso.
NO20070589L (no) Mitotiske kinesin-inhibitorer.
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
MX2007006554A (es) Procedimientos para preparar compuestos de indazol.
TW200801020A (en) Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines
UA92047C2 (uk) Карбоніламінопіролпіразоли - потужні інгібітори кінази
WO2007026221A3 (en) Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines
UA88794C2 (en) Pyrrolopyrazoles, potent kinase inhibitors
UA96742C2 (en) Mek inhibitors and use thereof